Novacyt (NCYT) Competitors

Novacyt logo
GBX 35.90 -0.50 (-1.37%)
As of 03:23 AM Eastern

NCYT vs. EKF, SPEC, CREO, IUG, and BVC

Should you buy Novacyt stock or one of its competitors? Novacyt's main competitors and comparable companies include EKF Diagnostics (EKF), INSPECS Group (SPEC), Creo Medical Group (CREO), Intelligent Ultrasound Group (IUG), and BATM Advanced Communications (BVC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment & supplies" industry.

How does Novacyt compare to EKF Diagnostics?

Novacyt (LON:NCYT) and EKF Diagnostics (LON:EKF) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.

In the previous week, Novacyt and Novacyt both had 1 articles in the media. Novacyt's average media sentiment score of 1.30 beat EKF Diagnostics' score of 0.00 indicating that Novacyt is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Novacyt
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
EKF Diagnostics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Novacyt has a beta of 1.112, indicating that its share price is 11% more volatile than the broader market. Comparatively, EKF Diagnostics has a beta of 0.503, indicating that its share price is 50% less volatile than the broader market.

EKF Diagnostics has a consensus target price of GBX 35, indicating a potential upside of 46.44%. Given EKF Diagnostics' stronger consensus rating and higher probable upside, analysts plainly believe EKF Diagnostics is more favorable than Novacyt.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novacyt
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
EKF Diagnostics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

EKF Diagnostics has a net margin of 4.86% compared to Novacyt's net margin of -102.66%. EKF Diagnostics' return on equity of 3.58% beat Novacyt's return on equity.

Company Net Margins Return on Equity Return on Assets
Novacyt-102.66% -159.13% -27.98%
EKF Diagnostics 4.86%3.58%5.27%

EKF Diagnostics has higher revenue and earnings than Novacyt. Novacyt is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novacyt£21.79M1.19-£36.80M-£31.00N/A
EKF Diagnostics£51.35M1.99£4.68M£0.5841.21

10.7% of Novacyt shares are held by institutional investors. Comparatively, 21.5% of EKF Diagnostics shares are held by institutional investors. 0.4% of Novacyt shares are held by company insiders. Comparatively, 40.2% of EKF Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

EKF Diagnostics beats Novacyt on 13 of the 15 factors compared between the two stocks.

How does Novacyt compare to INSPECS Group?

Novacyt (LON:NCYT) and INSPECS Group (LON:SPEC) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.

10.7% of Novacyt shares are owned by institutional investors. Comparatively, 0.7% of INSPECS Group shares are owned by institutional investors. 0.4% of Novacyt shares are owned by company insiders. Comparatively, 19.6% of INSPECS Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Novacyt and Novacyt both had 1 articles in the media. Novacyt's average media sentiment score of 1.30 beat INSPECS Group's score of 0.00 indicating that Novacyt is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Novacyt
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
INSPECS Group
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Novacyt has a beta of 1.112, indicating that its stock price is 11% more volatile than the broader market. Comparatively, INSPECS Group has a beta of 1.603, indicating that its stock price is 60% more volatile than the broader market.

INSPECS Group has higher revenue and earnings than Novacyt. INSPECS Group is trading at a lower price-to-earnings ratio than Novacyt, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novacyt£21.79M1.19-£36.80M-£31.00N/A
INSPECS Group£193.23M0.48-£4.11M-£5.34N/A

INSPECS Group has a net margin of -0.52% compared to Novacyt's net margin of -102.66%. INSPECS Group's return on equity of -1.19% beat Novacyt's return on equity.

Company Net Margins Return on Equity Return on Assets
Novacyt-102.66% -159.13% -27.98%
INSPECS Group -0.52%-1.19%0.45%

Summary

INSPECS Group beats Novacyt on 8 of the 12 factors compared between the two stocks.

How does Novacyt compare to Creo Medical Group?

Creo Medical Group (LON:CREO) and Novacyt (LON:NCYT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

Creo Medical Group has higher earnings, but lower revenue than Novacyt. Creo Medical Group is trading at a lower price-to-earnings ratio than Novacyt, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Creo Medical Group£7M6.58-£25.04M-£5.00N/A
Novacyt£21.79M1.19-£36.80M-£31.00N/A

In the previous week, Creo Medical Group and Creo Medical Group both had 1 articles in the media. Novacyt's average media sentiment score of 1.30 beat Creo Medical Group's score of 0.00 indicating that Novacyt is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Creo Medical Group
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Novacyt
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

44.0% of Creo Medical Group shares are held by institutional investors. Comparatively, 10.7% of Novacyt shares are held by institutional investors. 7.6% of Creo Medical Group shares are held by insiders. Comparatively, 0.4% of Novacyt shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Novacyt has a net margin of -102.66% compared to Creo Medical Group's net margin of -268.57%. Creo Medical Group's return on equity of -38.29% beat Novacyt's return on equity.

Company Net Margins Return on Equity Return on Assets
Creo Medical Group-268.57% -38.29% -20.09%
Novacyt -102.66%-159.13%-27.98%

Creo Medical Group has a beta of 1.563854, indicating that its stock price is 56% more volatile than the broader market. Comparatively, Novacyt has a beta of 1.112, indicating that its stock price is 11% more volatile than the broader market.

Summary

Creo Medical Group beats Novacyt on 8 of the 12 factors compared between the two stocks.

How does Novacyt compare to Intelligent Ultrasound Group?

Novacyt (LON:NCYT) and Intelligent Ultrasound Group (LON:IUG) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, media sentiment, profitability, valuation and dividends.

Intelligent Ultrasound Group has a net margin of -23.11% compared to Novacyt's net margin of -102.66%. Intelligent Ultrasound Group's return on equity of -23.58% beat Novacyt's return on equity.

Company Net Margins Return on Equity Return on Assets
Novacyt-102.66% -159.13% -27.98%
Intelligent Ultrasound Group -23.11%-23.58%-13.51%

10.7% of Novacyt shares are held by institutional investors. Comparatively, 75.5% of Intelligent Ultrasound Group shares are held by institutional investors. 0.4% of Novacyt shares are held by insiders. Comparatively, 12.8% of Intelligent Ultrasound Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Intelligent Ultrasound Group has lower revenue, but higher earnings than Novacyt. Novacyt is trading at a lower price-to-earnings ratio than Intelligent Ultrasound Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novacyt£21.79M1.19-£36.80M-£31.00N/A
Intelligent Ultrasound Group£6.57M0.00-£2.27M-£0.68N/A

In the previous week, Novacyt had 1 more articles in the media than Intelligent Ultrasound Group. MarketBeat recorded 1 mentions for Novacyt and 0 mentions for Intelligent Ultrasound Group. Novacyt's average media sentiment score of 1.30 beat Intelligent Ultrasound Group's score of 0.00 indicating that Novacyt is being referred to more favorably in the media.

Company Overall Sentiment
Novacyt Positive
Intelligent Ultrasound Group Neutral

Novacyt has a beta of 1.112, indicating that its stock price is 11% more volatile than the broader market. Comparatively, Intelligent Ultrasound Group has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market.

Summary

Intelligent Ultrasound Group beats Novacyt on 7 of the 12 factors compared between the two stocks.

How does Novacyt compare to BATM Advanced Communications?

Novacyt (LON:NCYT) and BATM Advanced Communications (LON:BVC) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

BATM Advanced Communications has higher revenue and earnings than Novacyt. BATM Advanced Communications is trading at a lower price-to-earnings ratio than Novacyt, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novacyt£21.79M1.19-£36.80M-£31.00N/A
BATM Advanced Communications£104.57M0.35-£278.26K-£3.94N/A

In the previous week, BATM Advanced Communications had 2 more articles in the media than Novacyt. MarketBeat recorded 3 mentions for BATM Advanced Communications and 1 mentions for Novacyt. Novacyt's average media sentiment score of 1.30 beat BATM Advanced Communications' score of 0.73 indicating that Novacyt is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Novacyt
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
BATM Advanced Communications
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Novacyt has a beta of 1.112, suggesting that its stock price is 11% more volatile than the broader market. Comparatively, BATM Advanced Communications has a beta of 0.754, suggesting that its stock price is 25% less volatile than the broader market.

BATM Advanced Communications has a net margin of -15.91% compared to Novacyt's net margin of -102.66%. BATM Advanced Communications' return on equity of -25.90% beat Novacyt's return on equity.

Company Net Margins Return on Equity Return on Assets
Novacyt-102.66% -159.13% -27.98%
BATM Advanced Communications -15.91%-25.90%0.58%

10.7% of Novacyt shares are owned by institutional investors. Comparatively, 14.3% of BATM Advanced Communications shares are owned by institutional investors. 0.4% of Novacyt shares are owned by company insiders. Comparatively, 31.0% of BATM Advanced Communications shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

BATM Advanced Communications beats Novacyt on 9 of the 13 factors compared between the two stocks.

Get Novacyt News Delivered to You Automatically

Sign up to receive the latest news and ratings for NCYT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NCYT vs. The Competition

MetricNovacytHealthcare Equipment & Supplies IndustryHealthcare SectorLON Exchange
Market Cap£26.04M£5.99B£7.83B£2.78B
Dividend YieldN/A1.68%2.47%5.11%
P/E Ratio-1.1637.4034.0023.20
Price / Sales1.195.398.485.01
Price / Cash0.5823.6221.0120.23
Price / Book0.364.174.462.48
Net Income-£36.80M£143.92M£3.52B£5.88B
7 Day Performance-1.64%-5.49%-5.94%-1.55%
1 Month Performance-9.11%-3.68%-4.59%-2.96%
1 Year Performance-5.53%-0.11%-1.93%7.77%

Novacyt Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NCYT
Novacyt
N/AGBX 35.90
-1.4%
N/A-5.8%£26.04M£21.79MN/A120
EKF
EKF Diagnostics
1.6409 of 5 stars
GBX 24.20
-0.8%
GBX 35
+44.7%
-9.0%£103.55M£51.35M41.72356
SPEC
INSPECS Group
N/AGBX 85
-2.9%
N/A+28.6%£92.80M£193.23MN/A1,673
CREO
Creo Medical Group
N/AGBX 10.45
+0.7%
GBX 40
+282.8%
-1.7%£46.94M£7MN/A279
IUG
Intelligent Ultrasound Group
N/AN/AN/AN/A£42.76M£6.57MN/A65

Related Companies and Tools


This page (LON:NCYT) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners